Roivant Sciences Ltd
ROIV27.670USD
+1.850+7.16%
收盤 02/09, 16:00（美東）報價延遲15分鐘
18.95B總市值
虧損本益比TTM
關於 Roivant Sciences Ltd 公司
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd簡介
公司代碼ROIV
公司名稱Roivant Sciences Ltd
上市日期Dec 03, 2020
CEOVenker (Eric)
員工數量750
證券類型Ordinary Share
年結日Dec 03
公司地址7Th Floor, 50 Broadway
城市LONDON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編SW1H 0DB
電話4412955950
網址http://roivant.com/
公司代碼ROIV
上市日期Dec 03, 2020
CEOVenker (Eric)
Roivant Sciences Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
41.26K
+761.00%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
37.59K
-148860.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-20494245.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+14524.00%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
+112255.00%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
100.84K
+1040.00%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.62K
+487.00%
收入明細
FY2025Q1
業務USD
名稱
營收
佔比
VTAMA
55.13M
0.00%
地區USD
名稱
營收
佔比
United States
55.13M
0.00%
業務
地區
業務USD
名稱
營收
佔比
VTAMA
55.13M
0.00%
股東統計
更新時間: 1月31日 週六
更新時間: 1月31日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Dexcel Pharma Technologies, Ltd.
14.37%
Fidelity Management & Research Company LLC
8.49%
Ramaswamy (Vivek)
6.58%
The Vanguard Group, Inc.
5.86%
Morgan Stanley Investment Management Inc. (US)
5.68%
其他
59.02%
持股股東
持股股東
佔比
Dexcel Pharma Technologies, Ltd.
14.37%
Fidelity Management & Research Company LLC
8.49%
Ramaswamy (Vivek)
6.58%
The Vanguard Group, Inc.
5.86%
Morgan Stanley Investment Management Inc. (US)
5.68%
其他
59.02%
股東類型
持股股東
佔比
Investment Advisor
30.17%
Investment Advisor/Hedge Fund
19.57%
Hedge Fund
14.79%
Corporation
14.37%
Individual Investor
10.31%
Private Equity
8.79%
Research Firm
1.60%
Pension Fund
0.49%
Venture Capital
0.45%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
728
545.59M
76.23%
-26.01M
2025Q3
690
526.70M
77.13%
-109.19M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Dexcel Pharma Technologies, Ltd.
102.85M
14.79%
--
--
Jul 01, 2025
Fidelity Management & Research Company LLC
60.73M
8.73%
+5.24M
+9.44%
Sep 30, 2025
Ramaswamy (Vivek)
47.07M
6.77%
-1.00
-0.00%
Dec 15, 2025
The Vanguard Group, Inc.
38.72M
5.57%
-521.41K
-1.33%
Sep 30, 2025
Morgan Stanley Investment Management Inc. (US)
40.65M
5.85%
+7.28M
+21.82%
Sep 30, 2025
SB Investment Advisers (UK) Limited
40.32M
5.8%
-19.64M
-32.76%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
35.76M
5.14%
+233.57K
+0.66%
Sep 30, 2025
QVT Financial LP
28.08M
4.04%
-1.30M
-4.42%
Nov 19, 2025
Viking Global Investors LP
23.59M
3.39%
-10.64M
-31.09%
Sep 30, 2025
Rubric Capital Management LP
20.00M
2.88%
-370.34K
-1.82%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco S&P MidCap 400 Pure Growth ETF
3.56%
Adaptiv Select ETF
2.91%
Virtus LifeSci Biotech Products ETF
2.79%
State Street SPDR S&P Biotech ETF
2.67%
WisdomTree US Value Fund
2.3%
ProShares Ultra Nasdaq Biotechnology
1.73%
Goldman Sachs Future Health Care Equity ETF
1.73%
Direxion Daily S&P Biotech Bull 3X Shares
1.41%
Invesco Nasdaq Biotechnology ETF
1.33%
WisdomTree BioRevolution Fund
1.3%
查看更多
Invesco S&P MidCap 400 Pure Growth ETF
佔比3.56%
Adaptiv Select ETF
佔比2.91%
Virtus LifeSci Biotech Products ETF
佔比2.79%
State Street SPDR S&P Biotech ETF
佔比2.67%
WisdomTree US Value Fund
佔比2.3%
ProShares Ultra Nasdaq Biotechnology
佔比1.73%
Goldman Sachs Future Health Care Equity ETF
佔比1.73%
Direxion Daily S&P Biotech Bull 3X Shares
佔比1.41%
Invesco Nasdaq Biotechnology ETF
佔比1.33%
WisdomTree BioRevolution Fund
佔比1.3%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
